Alpha, Beta, gamma human PapillomaViruses (HPV) detection with a different sets of primers in oropharyngeal swabs, anal and cervical samples.
Anal Canal
/ virology
Cervix Uteri
/ virology
DNA Primers
/ genetics
DNA, Viral
/ genetics
Female
Genotype
HIV Infections
/ complications
Humans
Male
Oropharynx
/ virology
Papillomaviridae
/ classification
Papillomavirus Infections
/ diagnosis
Phylogeny
Polymerase Chain Reaction
Prevalence
Retrospective Studies
Sequence Analysis, DNA
Viral Load
Betapapillomavirus
Gammapapillomavirus
HPV detection methods
HPV diagnosis
Human papillomaviruses
Oropharyngeal HPV infection
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
04 03 2019
04 03 2019
Historique:
received:
24
10
2018
accepted:
15
02
2019
entrez:
6
3
2019
pubmed:
6
3
2019
medline:
30
4
2019
Statut:
epublish
Résumé
Recent studies have shown a 13-fold increase of oropharyngeal cancer in the presence of HPV, while α-HPV detection seems to be rare in oral cavity in comparison to anal or cervical district, many novel β and γ types have been isolated in this anatomical site suggesting a wide tropism range. Currently, there are no guidelines recommending HPV oral cavity screening as a mandatory test, and it remains unknown which HPV types should be included in HPV screening programs. Our goal was to assess HPV prevalence in oropharyngeal, anal, and cervical swabs using different sets of primers,which are able to amplify α, β, γ HPV types. We analysed the presence of HPV DNA in oropharyngeal (n = 124), anal (n = 186), cervical specimens (n = 43) from HIV positive and negative patients using FAP59/64 and MY09/11 primers. All untyped strains were genetically characterized through PCR amplification and direct sequencing of partial L1 region, and the resulting sequences were classified through phylogenetic analysis. HPV prevalence was 20.9% in 124 oropharyngeal swab samples, including infections with multiple HPV types (5.6%). HPV prevalence in this anatomical site was significantly associated with serostatus: 63.3%in HIV positive and 36.3% in HIV negative patients (p < 0.05). Unclassified types were detected in 6 specimens. In our analysis, we did not observe any difference in HPV (α, β, γ) prevalence between men and women. Overall, β species were the most frequently detected 69.7%. When using anal swabs, for HIV positive patients, β genus prevalence was 1% and γ genus was 3.7% including 6 unclassified types. In cervical samples from 43 HIV positive women (18 HPV negative and 25 positive by MY09/11 PCR), only one sample was positivite for β This study provides new information about viral isolates present in oropharyngeal site and it will contribute to improve the monitoring of HPV infection.
Sections du résumé
BACKGROUND
Recent studies have shown a 13-fold increase of oropharyngeal cancer in the presence of HPV, while α-HPV detection seems to be rare in oral cavity in comparison to anal or cervical district, many novel β and γ types have been isolated in this anatomical site suggesting a wide tropism range. Currently, there are no guidelines recommending HPV oral cavity screening as a mandatory test, and it remains unknown which HPV types should be included in HPV screening programs. Our goal was to assess HPV prevalence in oropharyngeal, anal, and cervical swabs using different sets of primers,which are able to amplify α, β, γ HPV types.
METHODS
We analysed the presence of HPV DNA in oropharyngeal (n = 124), anal (n = 186), cervical specimens (n = 43) from HIV positive and negative patients using FAP59/64 and MY09/11 primers. All untyped strains were genetically characterized through PCR amplification and direct sequencing of partial L1 region, and the resulting sequences were classified through phylogenetic analysis.
RESULTS
HPV prevalence was 20.9% in 124 oropharyngeal swab samples, including infections with multiple HPV types (5.6%). HPV prevalence in this anatomical site was significantly associated with serostatus: 63.3%in HIV positive and 36.3% in HIV negative patients (p < 0.05). Unclassified types were detected in 6 specimens. In our analysis, we did not observe any difference in HPV (α, β, γ) prevalence between men and women. Overall, β species were the most frequently detected 69.7%. When using anal swabs, for HIV positive patients, β genus prevalence was 1% and γ genus was 3.7% including 6 unclassified types. In cervical samples from 43 HIV positive women (18 HPV negative and 25 positive by MY09/11 PCR), only one sample was positivite for β
CONCLUSION
This study provides new information about viral isolates present in oropharyngeal site and it will contribute to improve the monitoring of HPV infection.
Identifiants
pubmed: 30832688
doi: 10.1186/s12985-019-1132-x
pii: 10.1186/s12985-019-1132-x
pmc: PMC6398256
doi:
Substances chimiques
DNA Primers
0
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27Références
J Gen Virol. 1999 Sep;80 ( Pt 9):2437-43
pubmed: 10501499
Mol Biol Evol. 2000 Apr;17(4):540-52
pubmed: 10742046
Clin Cancer Res. 2000 Nov;6(11):4171-5
pubmed: 11106228
J Infect Dis. 2001 Feb 1;183(3):383-91
pubmed: 11133369
Int J Oncol. 2002 Aug;21(2):297-302
pubmed: 12118324
Nucleic Acids Res. 2002 Jul 15;30(14):3059-66
pubmed: 12136088
J Clin Pathol. 2004 May;57(5):449-55
pubmed: 15113849
J Clin Microbiol. 2005 Nov;43(11):5526-35
pubmed: 16272481
Bioinformatics. 2006 Nov 1;22(21):2688-90
pubmed: 16928733
J Clin Microbiol. 2006 Dec;44(12):4479-85
pubmed: 17021055
N Engl J Med. 2007 May 10;356(19):1944-56
pubmed: 17494927
Int J Cancer. 2009 Jul 15;125(2):362-6
pubmed: 19330833
J Virol Methods. 2009 Nov;161(2):280-3
pubmed: 19591874
Sex Transm Dis. 2010 Jun;37(6):386-91
pubmed: 20081557
Med Microbiol Immunol. 2012 May;201(2):117-25
pubmed: 21792749
J Infect Dis. 2011 Sep 1;204(5):787-92
pubmed: 21844305
J Natl Cancer Inst. 2011 Dec 21;103(24):1827-39
pubmed: 22158127
J Clin Virol. 2012 Jun;54(2):141-6
pubmed: 22437054
J Infect Dis. 2013 Oct 15;208(8):1335-41
pubmed: 23878325
Virology. 2013 Dec;447(1-2):300-11
pubmed: 24210127
J Clin Virol. 2014 Jan;59(1):30-7
pubmed: 24268765
J Clin Virol. 2014 Oct;61(2):237-41
pubmed: 25097015
Lancet Oncol. 2014 Nov;15(12):1319-31
pubmed: 25439690
Virology. 2015 Feb;476:341-344
pubmed: 25577151
J Vet Diagn Invest. 2015 Mar;27(2):221-5
pubmed: 25613043
J Infect. 2015 Jul;71(1):74-84
pubmed: 25698067
J Clin Virol. 2015 Jun;67:47-51
pubmed: 25959158
Clin Microbiol Infect. 2015 Sep;21(9):808-16
pubmed: 26003284
J Clin Virol. 2015 Nov;72:49-54
pubmed: 26397204
JAMA Dermatol. 2016 Dec 1;152(12):1354-1364
pubmed: 26720285
JAMA Oncol. 2016 Jan 21;:
pubmed: 26794505
BMC Cancer. 2016 Jul 20;16:510
pubmed: 27439470
J Clin Virol. 2016 Sep;82:159-165
pubmed: 27500365
Virus Res. 2017 Mar 2;231:128-138
pubmed: 27856220
J Gen Virol. 2017 Apr;98(4):519-526
pubmed: 28150575
Int J Cancer. 2017 Aug 15;141(4):664-670
pubmed: 28369882
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1312-1320
pubmed: 28377417
Open Forum Infect Dis. 2017 Jan 31;4(1):ofw216
pubmed: 28480229
J Infect Dis. 2017 Jul 1;216(1):92-96
pubmed: 28549147
Clin Microbiol Infect. 2018 Jan;24(1):29-36
pubmed: 28559000
Virology. 2017 Oct;510:55-59
pubmed: 28708973
Papillomavirus Res. 2017 Jun;3:160-167
pubmed: 28720451
BMC Infect Dis. 2018 Jan 8;18(1):25
pubmed: 29310590
Diagn Microbiol Infect Dis. 2018 Apr;90(4):267-271
pubmed: 29317137
Bioinformatics. 2018 Jun 15;34(12):1986-1995
pubmed: 29377990
J Clin Virol. 2018 Apr;101:74-85
pubmed: 29433017
Virology. 2018 Jun;519:74-76
pubmed: 29679790
Sci Rep. 2018 May 29;8(1):8241
pubmed: 29844517
J Infect Dis. 2018 Jul 2;218(3):388-397
pubmed: 29982800
Science. 1985 Dec 20;230(4732):1350-4
pubmed: 2999980
J Infect Dis. 1994 Nov;170(5):1077-85
pubmed: 7963696
Comput Appl Biosci. 1996 Dec;12(6):543-8
pubmed: 9021275
Cancer. 1997 Feb 1;79(3):595-604
pubmed: 9028373